Panthera Biopartners has secured private equity investment from Lloyds Development Capital
August 2025 — Panthera Biopartners had secured growth capital from Lloyds Development Capital Limited (LDC) to advance its geographic presence and enhance its clinical offering.
Panthera is one of the UK’s largest site management organizations (SMOs) for commercial clinical trials. Based in Preston, Lancashire, Panthera specializes in patient recruitment and the management of Phase II and Phase III clinical trials across a broad spectrum of therapeutic areas, including vaccines, cardiovascular medicine, diabetes, neurology, respiratory medicine, dermatology, rheumatology and early dementia. Its services span trial planning, data collection and patient retention. Operating six UK sites, Panthera conducts clinical trials for many of the world’s largest pharmaceutical companies and clinical research organizations (CROs).
LDC is a mid-market UK private equity firm. With LDC’s support, Panthera will seek to further expand its operations across the UK and Europe, increase the number of clinical sites, invest in technology and scale its trial delivery capabilities. As SMOs play an increasingly pivotal role in the drug development value chain, the business is well-positioned to capitalize on significant growth opportunities.
“We’re incredibly proud of what the team at Panthera has achieved and are excited to partner with LDC for this next phase of growth. Their investment will help us accelerate expansion, enhance our capabilities and continue delivering for our clients and patients. With LDC’s support and experience, we look forward to broadening our reach into Europe and expanding access to clinical trials across new regions,” said Stuart Young, CEO of Panthera.
Our role in the transaction
Oaklins S&W, based in the UK, acted as the management advisor to Panthera in securing private equity investment from LDC to support its ambitious growth strategy.
Talk to the deal team
Related deals
Litagra has been acquired by Infortar
Estonian investment company Infortar, through its subsidiary Infortar Agro, has acquired Litagra, one of Lithuania’s leading agricultural groups, from its founder Gintaras Kateiva, private equity firm Invalda INVL and Adomas Grigaitis. Following the transaction, Infortar has become the largest raw milk producer in the Baltic states. The transaction, valuing Litagra at an enterprise value of US$105 million, is one of the largest Estonian investments in Lithuania to date.
Learn moreValuation advisory has been provided to a co-investor in VDK
EMK Capital has transferred VDK Groep B.V. from EMK Capital Partners Fund I into the newly established US$1.4 billion single-asset continuation fund, the EMK VDK Partnership Fund, alongside a co-investment from EMK Capital Partners Fund III. The transaction, co-led by LGT Capital Partners and Coller EQT, provides existing investors with the opportunity to retain their exposure to VDK while securing additional capital to support the company’s continued growth and buy-and-build strategy.
Learn moreBe-Cloud has been acquired by PSG Equity
Be-Cloud, backed by B&Capital since 2021, has been acquired by PSG Equity, a leading growth equity firm specializing in software and technology-enabled services. The transaction marks the full exit of B&Capital and the reinvestment of Be-Cloud’s founders, Lenny and Sébastien Vercruysse, alongside PSG Equity.
Learn more